Next Article in Journal
Health-Related Quality of Life in Adrenocortical Carcinoma
Next Article in Special Issue
The CD73/Ado System—A New Player in RT Induced Adverse Late Effects
Previous Article in Journal
Long-Term Outcomes of Stereotactic Radiosurgery for Vestibular Schwannoma Associated with Neurofibromatosis Type 2 in Comparison to Sporadic Schwannoma
Previous Article in Special Issue
γ-H2AX Foci Persistence at Chromosome Break Suggests Slow and Faithful Repair Phases Restoring Chromosome Integrity
Open AccessReview

Implementation of the Chick Chorioallantoic Membrane (CAM) Model in Radiation Biology and Experimental Radiation Oncology Research

1
Institute for Anatomy II, Department of Neuroanatomy, University of Duisburg-Essen, University Medicine Essen, 45122 Essen, Germany
2
Institute of Cell Biology (Cancer Research), University of Duisburg-Essen, University Medicine Essen, 45122 Essen, Germany
*
Authors to whom correspondence should be addressed.
Cancers 2019, 11(10), 1499; https://doi.org/10.3390/cancers11101499
Received: 2 September 2019 / Revised: 19 September 2019 / Accepted: 20 September 2019 / Published: 7 October 2019
Radiotherapy (RT) is part of standard cancer treatment. Innovations in treatment planning and increased precision in dose delivery have significantly improved the therapeutic gain of radiotherapy but are reaching their limits due to biologic constraints. Thus, a better understanding of the complex local and systemic responses to RT and of the biological mechanisms causing treatment success or failure is required if we aim to define novel targets for biological therapy optimization. Moreover, optimal treatment schedules and prognostic biomarkers have to be defined for assigning patients to the best treatment option. The complexity of the tumor environment and of the radiation response requires extensive in vivo experiments for the validation of such treatments. So far in vivo investigations have mostly been performed in time- and cost-intensive murine models. Here we propose the implementation of the chick chorioallantoic membrane (CAM) model as a fast, cost-efficient model for semi high-throughput preclinical in vivo screening of the modulation of the radiation effects by molecularly targeted drugs. This review provides a comprehensive overview on the application spectrum, advantages and limitations of the CAM assay and summarizes current knowledge of its applicability for cancer research with special focus on research in radiation biology and experimental radiation oncology. View Full-Text
Keywords: chorioallantoic membrane assay; CAM; radiation; radiotherapy; radioresistance; hypoxia; cancer; tumor; molecularly targeted drugs; tumor microenvironment chorioallantoic membrane assay; CAM; radiation; radiotherapy; radioresistance; hypoxia; cancer; tumor; molecularly targeted drugs; tumor microenvironment
Show Figures

Graphical abstract

MDPI and ACS Style

Dünker, N.; Jendrossek, V. Implementation of the Chick Chorioallantoic Membrane (CAM) Model in Radiation Biology and Experimental Radiation Oncology Research. Cancers 2019, 11, 1499.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop